1-12 of 12
Anuja Roy, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluation of Treatment Outcomes after Second-Line Treatment Among Adult Patients with Immune Thrombocytopenia

Qayyim Said, PhD, Lincy S Lal, PhD, Brigette Nezami, PharmD, Katherine Andrade, J. Anthony Graves, MD, PhD, Anuja Roy, PhD, Adam Cuker, MD MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 3765.
https://doi.org/10.1182/blood-2018-99-115197
Published: 2018
Journal Articles

Bleeding Related Episodes, Thrombotic Events and Platelet Counts Among Immune Thrombocytopenia Patients Receiving Second Line Therapy

Qayyim Said, PhD, Lincy S Lal, PhD, Katherine Andrade, Brigette Nezami, PharmD, J. Anthony Graves, MD, PhD, Anuja Roy, PhD, Adam Cuker, MD MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 2436.
https://doi.org/10.1182/blood-2018-99-111975
Published: 2018
Journal Articles

Comparing Costs and Consequences of Eltrombopag Plus IST Versus IST Alone for First-Line Treatment in Severe Aplastic Anemia: Results from a Responder Analysis

Gabriel Tremblay, DBA, MSc, BS, Qayyim Said, PhD, Beilei Cai, PhD MA, Shan Ashton Garib, MA, Dimitrios Tomaras, MSc, Anna Forsythe, PharmD, MSc, MBA, Anuja Roy, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1041.
https://doi.org/10.1182/blood-2018-99-115138
Published: 2018
Journal Articles

Benefit-Risk Comparison in Patients with Immune Thrombocytopenia (ITP) Receiving Eltrombopag or Romiplostim: Real World Evidence (RWE) from 26 Hospital Institutions

Anna Forsythe, PharmD, MSc, MBA, Anuja Roy, PhD, Menaka Bhor, PhD, Alex Allepuz, MD MPH, Maria Do Socorro Oliveira Portella, MD MBA, Christina Kwon, BSc, MSc, PhD, Gabriel Tremblay, DBA, MSc, BS
Journal: Blood
Blood (2017) 130 (Supplement 1): 3409.
https://doi.org/10.1182/blood.V130.Suppl_1.3409.3409
Published: 2017
Journal Articles

A Canadian Cost-Effectiveness Analysis for the Treatment of Immune Thrombocytopenia: Assessing the Relative Value of with Eltrombopag Versus Romiplostim

Gabriel Tremblay, DBA, MSc, BS, Mike Dolph, MSc BHSc, Anuja Roy, PhD, Juliette Neyra, PharmD, Khalid El Ouagari, Anna Forsythe, PharmD, MSc, MBA
Journal: Blood
Blood (2017) 130 (Supplement 1): 3410.
https://doi.org/10.1182/blood.V130.Suppl_1.3410.3410
Published: 2017
Journal Articles

Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia

Gabriel Tremblay, DBA, MSc, BS, Menaka Bhor, PhD, Anuja Roy, PhD, Brian Elliott, MD, Mike Dolph, MSc BHSc, Anna Forsythe, PharmD, MSc, MBA, Andrew Briggs, DPhil
Journal: Blood
Blood (2017) 130 (Supplement 1): 2146.
https://doi.org/10.1182/blood.V130.Suppl_1.2146.2146
Published: 2017
Journal Articles

A Retrospective Chart Review to Assess Burden of Illness Among Patients with Severe Aplastic Anemia with Insufficient Response to Immunosuppressive Therapy

Regis Peffault De Latour, MD PhD, Lynn Huynh, Jasmina I. Ivanova, Todor Totev, BSc, Mehmet Bilginsoy, BA, Joseph H. Antin, MD, Anuja Roy, PhD, Mei Sheng Duh, MPH, ScD
Journal: Blood
Blood (2017) 130 (Supplement 1): 678.
https://doi.org/10.1182/blood.V130.Suppl_1.678.678
Published: 2017
Journal Articles

Evaluation of Treatment Patterns Among Patients with Newly Diagnosed, Persistent, and Chronic Immune Thrombocytopenia (ITP) Treated with Eltrombopag in Real World Setting in the US

Dana Stafkey-Mailey, PharmD, PhD, Anuja Roy, PhD, Tasneem Lokhandwala, BPharm, MS, PhD, Jing Yuan, Pamela Landsman-Blumberg, MPH DrPH, Asif Siddiqui, PhD, Farhat Ghaznawi, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2078.
https://doi.org/10.1182/blood.V130.Suppl_1.2078.2078
Published: 2017
Journal Articles

Eltrombopag Compared to Rituximab Improves the Probability of Response in Adult Chronic ITP Patients

Alexander Hirst, MSc, Jing Wang-Silvanto, PhD, Cal Shephard, MSc, Anuja Roy, PhD
Journal: Blood
Blood (2016) 128 (22): 2334.
https://doi.org/10.1182/blood.V128.22.2334.2334
Published: 2016
Journal Articles

Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs

Sundar Jagannath, MD, Anuja Roy, PhD, Jonathan K Kish, PhDMPH, Denise Globe, PhD, Orsolya Lunacsek, PhDMBA, Michael T. Eaddy, PharmD, PhD, Emil T Kuriakose, MD, Joanne Willey, RN, David Siegel, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3311.
https://doi.org/10.1182/blood.V126.23.3311.3311
Published: 2015
Journal Articles

Costs per Month Free of Progression or Death of Targeted Therapies in the Treatment of Relapsed/Refractory Multiple Myeloma

Hongbo Yang, PhD, Anuja Roy, PhD, Chelsey Yang, Evangeline McDonald, Arun Krishna, PhD, Emil T Kuriakose, MD, Denise Globe, PhD, David Siegel, MD PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2015) 126 (23): 5369.
https://doi.org/10.1182/blood.V126.23.5369.5369
Published: 2015
Journal Articles

Comparison of Real-World Treatment Patterns and Clinical Outcomes in 18-59 Year-Old Patients with FLT3 Mutated Vs. FLT3 Wild Type Acute Myeloid Leukemia: A Medical Records Review

Jipan Xie, MD PhD, Emily Goldmann, MPH, PhD, Anuja Roy, PhD MBA, Chelsey Yang, BA, Eric Q Wu, PhD, Carole Paley, MD
Journal: Blood
Blood (2014) 124 (21): 5992.
https://doi.org/10.1182/blood.V124.21.5992.5992
Published: 2014